Investors

2025 Full year and fourth quarter results announcement

We will announce our full year and fourth quarter 2025 results on 4 February at 07:00 GMT, 02:00 EST.

Quarterly results Register for the webcast

Our purpose

We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

Purpose, strategy and culture

Why invest in GSK?

Respiratory, immunology and inflammation

deaths each year due to lung diseases

Go to respiratory, immunology and inflammation

Oncology

~10m

people died from cancer in 2022, making it a leading cause of death worldwide

Go to oncology

HIV

40m

people living with HIV globally

Go to HIV

Infectious diseases

1 in 6

deaths globally caused by infectious disease

Go to infectious diseases

Behind the Science

Discover how we're getting ahead

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

‘This could be a golden moment’: Is prevention the ‘medicine’ we need to end the HIV epidemic?

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

Read our magazine

Life at GSK

Find out what it's like to work with us

Make a difference with us

Do your best work with us

Be yourself with us

Careers at GSK

Positively impacting society and the planet

Access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Access

Global health and health security

We are committed to change the trajectory of high burden diseases in lower-income countries with a focus on prevention and treatment of infectious diseases.

Global health and health security

Environment

We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Environment

Inclusion

To be a successful business and deliver positive health impact at scale, we must meet patients’ needs with research that includes those impacted by the disease under study, attract and retain the best talent regardless of background, and support all GSK people to thrive.

Inclusion

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Ethical standards

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

Product governance

INVESTORS

We will announce our full year and fourth quarter 2025 results on Wednesday 4 February

View latest results